Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study

Vaccine

Volumn 33, Issue 9, 2015, Pages 1135-1142

  Regev Yochay, Gili ^a   Paran, Yael ^b   Bishara, Jihad ^c   Oren, Ilana ^d   Chowers, Michal ^e   Tziba, Yevgenia ^f   Istomin, Valery ^g   Weinberger, Miriam ^h   Miron, Dan ⁱ   Temper, Violeta ^j   Rahav, Galia ^a   Dagan, Ron ^k  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

^f BARZILAI MEDICAL CENTER   (Israel)

^g HILLEL YAFFE MEDICAL CENTER   (Israel)

^h ASSAF HAROFEH MEDICAL CENTER   (Israel)

ⁱ Rebecca Sieff Government Hospital   (Israel)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

more..

Author keywords

Adult invasive pneumococcal disease; Herd effect; Nationwide active surveillance; PCV13 impact; PCV7

Indexed keywords

CEFTRIAXONE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE; 13-VALENT PNEUMOCOCCAL VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADULT; ADULT DISEASE; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BEDOUIN; CEREBROSPINAL FLUID; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG UPTAKE; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ISRAEL; ISRAELI; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEASONAL VARIATION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SUMMER; TREATMENT PLANNING; VACCINATION; WINTER; YOUNG ADULT; ADOLESCENT; EPIDEMIOLOGICAL MONITORING; FEMALE; INFANT; MALE; MENINGITIS, BACTERIAL; PNEUMOCOCCAL INFECTIONS; PREVENTIVE HEALTH SERVICE; SEPSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; ISRAEL; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SEPSIS; YOUNG ADULT;

EID: 84922772379     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.030     Document Type: Article

References (23)

1. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30(2):189-209. (Epub 2009/03/20).
2. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41. (Epub 2009/12/02).
3. Ardanuy C., Tubau F., Pallares R., Calatayud L., Dominguez M.A., Rolo D., et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009, 48(1):57-64. (Epub 2008/11/28; an official publication of the Infectious Diseases Society of America).
4. Lehmann D., Willis J., Moore H.C., Giele C., Murphy D., Keil A.D., et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010, 50(11):1477-1486. (Epub 2010/04/28; an official publication of the Infectious Diseases Society of America).
5. van der Linden M., Weiss S., Falkenhorst G., Siedler A., Imohl M., von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012, 30(40):5880-5885. (Epub 2012/07/10).
6. Simonsen L., Taylor R.J., Schuck-Paim C., Lustig R., Haber M., Klugman K.P. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Respiratory medicine 2014, 2(5):387-394. (Epub 2014/05/13).
7. Moore C.E., Paul J., Foster D., Mahar S.A., Griffiths D., Knox K., et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 2014, Oct 1; 210(7):1001-1011. (Epub 2014/04/11).
8. van Hoek A.J., Sheppard C.L., Andrews N.J., Waight P.A., Slack M.P., Harrison T.G., et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 2014, 32(34):4349-4355. (Epub 2014/03/25).
9. Regev-Yochay G., Rahav G., Strahilevitz J., Bishara J., Katzir M., Chowers M., et al. A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7. Vaccine 2013, 31(19):2387-2394. (Epub 2013/03/23).
10. Ben-Shimol S., Greenberg D., Givon-Lavi N., Elias N., Glikman D., Rubinstein U., et al. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the national immunization plan in Israel. Vaccine 2012, 30(46):6600-6607. (Epub 2012/09/04).
11. Regev-Yochay G., Rahav G., Riesenberg K., Wiener-Well Y., Strahilevitz J., Stein M., et al. Initial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease in Israel. PLoS ONE 2014, 9(2):e88406. (Epub 2014/02/12).
12. Pichon B., Ladhani S.N., Slack M.P., Segonds-Pichon A., Andrews N.J., Waight P.A., et al. Changes in molecular epidemiology of Streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol 2013, 51(3):820-827. (Epub 2012/12/28).
13. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Andersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28(14):2642-2647. (Epub 2010/01/26).
14. Meichtry J., Born R., Kuffer M., Zwahlen M., Albrich W.C., Brugger S.D., et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine 2014, 32(40):5185-5191. (Epub 2014/08/01).
15. Torne A.N., Dias J.G., Quinten C., Hruba F., Busana M.C., Lopalco P.L., et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 2014, 32(29):3644-3650. (Epub 2014/05/06).
16. Ben-Shimol S., Greenberg D., Givon-Lavi N., Schlesinger Y., Somekh E., Aviner S., et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 2014, 32(27):3452-3459. (Epub 2014/04/03).
17. Ladhani S.N., Slack M.P., Andrews N.J., Waight P.A., Borrow R., Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013, 19(1):61-68. (Epub 2012/12/25).
18. Cooper D., Yu X., Sidhu M., Nahm M.H., Fernsten P., Jansen K.U. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011, 29(41):7207-7211. (Epub 2011/06/22).
19. Cohen R., Levy C., Bingen E., Koskas M., Nave I., Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012, 31(3):297-301. (Epub 2012/02/15).
20. Horacio A.N., Diamantino-Miranda J., Aguiar S.I., Ramirez M., Melo-Cristino J. The majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5. PLoS ONE 2013, 8(9):e73704. (Epub 2013/09/26).
21. Burgos J., Lujan M., Falco V., Sanchez A., Puig M., Borrego A., et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 2011, 53(3):254-261. (Epub 2011/07/19; an official publication of the Infectious Diseases Society of America).
22. Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008, 8(12):785-795. (Epub 2008/11/22).
23. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Beekmann S.E., Doern G.V. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48(3):e23-e33. (Epub 2009/01/01; an official publication of the Infectious Diseases Society of America).